ArticleBMC gastroenterology2010
Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.
Article in BMC gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 27 citations in OpenAlex.
- Management of liver disease and portal hypertension in common variable immunodeficiency (CVID).JHEP reports : innovation in hepatology · 2023Review
- Idiopathic Noncirrhotic Portal Hypertension: An Appraisal.Journal of pathology and translational medicine · 2016Review
- Idiopathic non-cirrhotic portal hypertension: a review.Orphanet journal of rare diseases · 2015Review
- Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.World journal of hepatology · 2014Review
- Non-cirrhotic portal hypertension in the HIV-infected individual.Journal of the Royal Society of Medicine · 2013Article
- Human immunodeficiency virus infection and the liver.World journal of hepatology · 2012Article
- Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient.BMJ case reports · 2012Article
- Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.World journal of gastroenterology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNodular regenerative hyperplasia (NRH) has been recently recognized as an emergent cause of liver disease in HIV-infected patients. NRH may cause non-cirrhotic portal hypertension with potentially severe consequences such as refractory ascites, variceal bleeding and hypersplenism. Obliteration of the small intrahepatic portal veins in association with prothrombotic disorders linked to HIV infection itself or anti-retroviral therapy seem to be the causes of NRH and thus the term HIV-associated obliterative portopathy has been proposed. CASE PRESENTATION: Here we describe a case of a HIV-infected patient with biopsy-proven NRH and listed for liver transplantation (LT) because of refractory ascites and repeated upper gastrointestinal bleedings. A transjugular intrahepatic portosystemic shunt was placed as a bridge to LT and did not improve liver function. However, anticoagulant therapy with low-molecular-weight heparin (LMWH) was associated with rapid improvement in the liver condition and allowed to avoid LT in this patient.
conclusionsThus, this case underscores the relation between thrombophilia and HIV-associated NRH and emphasizes anticoagulant therapy as possible treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.